YD Bio and EG BioMed Launch AI-Based Cancer Risk Assessment
YD Bio and EG BioMed have launched an AI-based assessment for 10 cancer risk factors. YD Bio is advancing DNA methylation-based cancer detection technology.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.